Market open
Xtant Medical/$XTNT
Xtant Medical shares are trading higher after the company announced preliminary Q1 revenue growth of 18% to 19% and a secondary private sale of shares by OrbiMed.
2 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xtant Medical
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Ticker
$XTNT
Sector
Trading on
AMEX
Industry
Health Care Equipment & Supplies
Headquarters
Employees
225
Website
Xtant Medical Metrics
BasicAdvanced
$55M
-
-$0.12
0.41
-
Price and volume
Market cap
$55M
Beta
0.41
52-week high
$0.97
52-week low
$0.33
Average daily volume
56K
Financial strength
Current ratio
2.348
Quick ratio
0.94
Long term debt to equity
51.791
Total debt to equity
81.798
Interest coverage (TTM)
-2.90%
Management effectiveness
Return on assets (TTM)
-8.09%
Return on equity (TTM)
-34.88%
Valuation
Price to revenue (TTM)
0.45
Price to book
1.28
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
-3.298
Growth
Revenue change (TTM)
28.44%
Earnings per share change (TTM)
-2,320.92%
3-year revenue growth (CAGR)
28.50%
3-year earnings per share growth (CAGR)
27.05%
What the Analysts think about Xtant Medical
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Xtant Medical stock.
Xtant Medical Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Xtant Medical Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Xtant Medical News
AllArticlesVideos
Xtant Medical Holdings, Inc. (XTNT) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Accesswire·1 month ago
Xtant Medical to Issue Fourth Quarter and Year End 2024 Financial Results on March 6, 2025
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Xtant Medical stock?
Xtant Medical (XTNT) has a market cap of $55M as of April 17, 2025.
What is the P/E ratio for Xtant Medical stock?
The price to earnings (P/E) ratio for Xtant Medical (XTNT) stock is 0 as of April 17, 2025.
Does Xtant Medical stock pay dividends?
No, Xtant Medical (XTNT) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Xtant Medical dividend payment date?
Xtant Medical (XTNT) stock does not pay dividends to its shareholders.
What is the beta indicator for Xtant Medical?
Xtant Medical (XTNT) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.